RHYTHM PHARMACEUTICALS, INC. 10-Q

Item 5. Other Information (a) Disclosure in lieu of reporting on a Current Report on Form 8-K. None. (b) Material changes to the procedures by which security holders may recommend nominees to the board of directors. None. (c) Insider Trading Arrangements and Policies. On August 8, 2024 , Jospeh Shulman , the Company’s Chief Technical Officer , adopted a trading plan intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act for the sale of up to 73,203 shares of the Company’s common stock until November 5, 2025 . On August 8, 2024 , Jennifer Kayden Lee , the Company’s EVP, Head of North America , adopted a trading plan intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act for the sale of up to 71,050 shares of the Company’s common stock until September 1, 2025 . Other than as disclosed above, during the three months ended September 30, 2024, no director or officer of the Company adopted or terminated a “ Rule 10b5-1 trading arrangement ” or “ non-Rule 10b5-1 trading arrangement ,” as each term is defined in Item 408(a) of Regulation S-K. Item 6. Exhibits ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Incorporated by Reference Exhibit Number Exhibit Description Form Date Number 3.1 ​ Amended and Restated Certificate of Incorporation. ​ 10-Q ​ 05/04/2020 ​ 3.1 3.2 ​ Amended and Restated Bylaws. ​ 8-K ​ 12/18/2023 ​ 3.1 3.3 ​ Certificate of Designations ​ 8-K ​ 04/16/2024 ​ 3.1 3.4 ​ Amended and Restated Certificate of Designations ​ 10-Q ​ 05/07/2024 ​ 3.4 31.1* ​ Certification of the Principal Executive Officer, as required by Section 302 of the Sarbanes-Oxley Act of 2002 (18 U.S.C. 1350). ​ ​ ​ ​ ​ ​ 106 Table of Contents 31.2* ​ Certification of the Principal Financial Officer, as required by Section 302 of the Sarbanes-Oxley Act of 2002 (18 U.S.C. 1350). ​ ​ ​ ​ ​ ​ 32.1** ​ Certification of the Principal Executive Officer, as required by Section 906 of the Sarbanes-Oxley Act of 2002 (18 U.S.C. 1350). ​ ​ ​ ​ ​ ​ 32.2** ​ Certification of the Principal Financial Officer, as required by Section 906 of the Sarbanes-Oxley Act of 2002 (18 U.S.C. 1350). ​ ​ ​ ​ ​ ​ 101.INS* ​ Inline XBRL Instance Document - the Instance Document does not appear in the interactive data file because its XBRL tags are embedded within the Inline XBRL document. ​ ​ ​ ​ ​ ​ 101.SCH* ​ Inline XBRL Taxonomy Extension Schema Document. ​ ​ ​ ​ ​ ​ 101.CAL* ​ Inline XBRL Taxonomy Extension Calculation Linkbase Document. ​ ​ ​ ​ ​ ​ 101.DEF* ​ Inline XBRL Taxonomy Extension Definition Linkbase Document. ​ ​ ​ ​ ​ ​ 101.LAB* ​ Inline XBRL Taxonomy Extension Label Linkbase Document. ​ ​ ​ ​ ​ ​ 101.PRE* ​ Inline XBRL Taxonomy Extension Presentation Linkbase Document. ​ ​ ​ ​ ​ ​ 104* ​ Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101). ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ * Filed herewith. ** Furnished herewith. ​ ​ ​ SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. ​ RHYTHM PHARMACEUTICALS, INC. ​ ​ ​ Dated: November 6, 2024 By: /s/ David P. Meeker, M.D. ​ ​ Name: David P. Meeker, M.D. ​ ​ Title: President and Chief Executive Officer ​ ​ (Principal Executive Officer) ​ ​ ​ Dated: November 6, 2024 By: /s/ Hunter C. Smith ​ ​ Name: Hunter C. Smith ​ ​ Title: Chief Financial Officer and Treasurer ​ ​ (Principal Financial Officer) ​ ​ 107